Account Info
Log Out

Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Up 22.5% in November

Financial News Live ·  12/16/2022 05:31

Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 19,600 shares, an increase of 22.5% from the November 15th total of 16,000 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average daily volume of 16,900 shares, the short-interest ratio is presently 1.2 days.

Analyst Ratings Changes

A number of research analysts have recently weighed in on TPST shares. William Blair restated an "outperform" rating on shares of Tempest Therapeutics in a research report on Tuesday, November 8th. LADENBURG THALM/SH SH started coverage on Tempest Therapeutics in a research report on Thursday, September 15th. They set a "buy" rating and a $8.00 price objective for the company.

Get Tempest Therapeutics alerts:

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tempest Therapeutics stock. Millennium Management LLC bought a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,675 shares of the company's stock, valued at approximately $29,000. Millennium Management LLC owned 0.13% of Tempest Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 50.26% of the company's stock.

Tempest Therapeutics Stock Up 2.7 %

TPST traded up $0.04 on Thursday, hitting $1.50. The company had a trading volume of 148 shares, compared to its average volume of 102,291. Tempest Therapeutics has a 12-month low of $1.42 and a 12-month high of $7.18. The company has a current ratio of 2.50, a quick ratio of 2.50 and a debt-to-equity ratio of 0.44. The business's fifty day simple moving average is $1.69 and its 200 day simple moving average is $2.10.

Tempest Therapeutics Company Profile

(Get Rating)

Tempest Therapeutics Inc, a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors.

Read More

  • Get a free copy of the research report on Tempest Therapeutics (TPST)
  • This is no Time to Buy Lennar but the Time is Coming
  • Game-Changing News For Mullen Automotive
  • Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
  • Is Enterprise Products Partners Fairly Valued?
  • Will WhatsApp Partnership Boost MercadoLibre's Earnings?

Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites and Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.